Skip to main content

Home/ MaRS/ Group items matching "medicine" in title, tags, annotations or url

Group items matching
in title, tags, annotations or url

Sort By: Relevance | Date Filter: All | Bookmarks | Topics Simple Middle
Melissa Hughes

Wearable sensor-monitoring technology could change preventative medicine forever - Techvibes - March 19, 2013 - 1 views

www.techvibes.com/...nitoring-technology-2013-03-19

Clients InteraXon wearable technology Muse Ariel Garten

shared by Melissa Hughes on 19 Mar 13 - No Cached
  • Karen Schulman Dupuis on 19 Mar 13
     
    Garten's headband is called Muse, a fashion-forward brainwave sensing wearable device which monitors and collects data from your brain and sends to your smartphone or tablet. Think this sounds like a concept we will see only in the future? Think again. This device is expected to hit the market later this year.
Assunta Krehl

A Living Legacy - The Scientist - June 3, 2010 - 0 views

www.the-scientist.com/...57426

Clients & Tenants McLaughlin Centre for Molecular Medicine Hospital for Sick Children Life Sciences Stem Cells

shared by Assunta Krehl on 07 Jun 10 - Cached
  • Assunta Krehl on 07 Jun 10
     
    The Stem Cell Network, a national organization founded by the Canadian government in 2001 that today is more than 100 investigators strong and has received over $60 million in government funding. The Stem Cell Network is helping to create a vibrant and interactive community.
Cathy Bogaart

OGI Invests in Personalized Medicine for Age-related Macular Degeneration - November 1, 2010 - 0 views

www.ontariogenomics.ca/...597

clients clients & tenants arcticdx life sciences health care diagnostics

shared by Cathy Bogaart on 02 Nov 10 - No Cached
  • Cathy Bogaart on 02 Nov 10
     
    The Ontario Genomics Institute has given funding to MaRS life sciences client, ArcticDX. They'll use the money for studies in preparation for a Food and Drug Administration approval for their product. The funding comes through its Pre-Commercialization Business Development Fund (PBDF)
Assunta Krehl

The business side to good health - The Star - 0 views

www.thestar.com/...692636

commercialization Ivey Centre for Health Innovation and Leadership Hospital for Sick Children

shared by Assunta Krehl on 10 Sep 09 - Cached
  • The Ivey Centre for Health Innovation and Leadership was launched this year with a $5-million push from the Canadian government. The latest Ivey initiative has the goal of bringing students together with experts from the science and business sectors, with the ultimate goal of better identifying and commercializing health technologies.Dr. Kellie Leitch, a Hospital for Sick Children orthopedic surgeon, is the first executive director of the centre, which is based at Western.
  • She is sitting in the basement of MaRS, a scientific hub of activity in downtown Toronto where labs, business and major Toronto teaching hospitals are brought together under one roof.
  • The Ivey centre will focus on giving the educational capability to our students so they become really well educated in innovation and commercialization, so we can keep things here at home in Canada and grow those products."
  • ...2 more annotations...
  • A good example of where both business and health-care expertise is needed is at Crown agencies such as eHealth Ontario.
  • The new Ivey centre builds on a partnership with the London Health Sciences Centre and the Schulich School of Medicine and Dentistry
  • Assunta Krehl on 10 Sep 09
     
    The Ivey Centre for Health Innovation and Leadership was launched in 2009. The goal of this initiative is to bring students together together with experts from the science and business sectors, with the ultimate goal of better identifying and commercializing health technologies.Dr. Kellie Leitch, a Hospital for Sick Children orthopedic surgeon, is the first executive director of the centre, which is based at Western. Sept 10, 2009
Assunta Krehl

Bridging Medicine's Great Divide - The Star - 0 views

docs.google.com/gview

MaRS collaboration mobile Ilse Treurnicht John Evans Wallace Wireless Peter Evans Xplane digniche Canadian Program on Genomics and Global Health

shared by Assunta Krehl on 27 Aug 09 - No Cached
  • Assunta Krehl on 27 Aug 09
     
    MaRS celebrates its first anniversary. Judy Steed, Toronto Star Reporter, caputures some of the people, ideas and developments in commercializing leading edge research at the MaRS Centre.
  • Assunta Krehl on 27 Aug 09
     
    MaRS celebrates its first anniversary. Judy Steed, Toronto Star Reporter, caputures some of the people, ideas and developments in commercializing leading edge research at the MaRS Centre. Sept 26, 2006
Assunta Krehl

Speech that might have been - The Star - 0 views

docs.google.com/gview

economy McEwan Centre for Regenerative Medicine

shared by Assunta Krehl on 27 Aug 09 - No Cached
  • Assunta Krehl on 27 Aug 09
     
    Stephane Dion , elected leader of the federal Liberals outlines his economic blueprint for the 21st century that will prepare Canadians for the "innovation economy."
  • Assunta Krehl on 27 Aug 09
     
    Stephane Dion , elected leader of the federal Liberals outlines his economic blueprint for the 21st century that will prepare Canadians for the "innovation economy." Dec 3, 2006
Assunta Krehl

Building a Successful Biotech Incubator - 0 views

www.genengnews.com/...chitem_print.aspx

entrepreneurs mars education raising capital

shared by Assunta Krehl on 31 Jul 09 - Cached
  • MaRS aggregates the discovery pipelines of its member institutions, which include three universities, 10 academic teaching hospitals, and the Ontario Institute for Cancer Research.
  • MaRS is another good example. Located in the heart of downtown Toronto, the MaRS facility is less than a mile from five major teaching hospitals, the Ontario legislature, and the University of Toronto. More than two dozen research institutes and Toronto’s financial district are also nearby.
  • Consequently, MaRS is a vertical incubator, with a wide variety of companies and stages of development. That mix helps companies better understand the conditions that foster growth. MaRS is home to more than 65 organizations, including The Hospital for Sick Children, the Ontario Institute for Cancer Research, Merck Frosst Canada, the McEwen Centre for Regenerative Medicine, Celtic House Venture Partners, AIM Therapeutics, and AstraZeneca Canada.
  • ...3 more annotations...
  • “Collaboration is the essence of the new economy,” insists Ross Wallace, director of strategic partnerships at MaRS. “There’s a new focus on the power of institutions to generate intellectual property and ideas, and then build around them.”
  • MaRS has a virtual education program dubbed “Entrepreneurship 101.” One February class features budgeting, another agrifood innovation. The classes are available at no cost, and anyone can register. The program also includes blogs and discussion groups such as the drug development and cancer targets groups. So far, MaRS has relied on viral marketing to get the word out.
  • To provide that expertise, MaRS developed the MaRS Venture Group. This team of experienced investors, entrepreneurs, technology experts, and advisors works with companies to help them bridge the gap between entrepreneurial start-up and experienced growth company. The Venture Group provides market intelligence as well  as advisory services such as strategic planning, partnership and alliance building, intellectual property management, marketing and communications, sales strategy, channel development, financing, and human resource development. It works with groups outside the MaRS orbit, too.
  • Assunta Krehl on 31 Jul 09
     
    To have a successful biotech initiative proximity to academic hubs and capital remains a crucial factor in hatching a thriving cluster. MaRS Discovery District is a good example of a vertical incubator and offers many services to help entrepreneurs at different stages.
Assunta Krehl

Researcher's Kyoto Prize celebrated - University of Toronto - 0 views

www.news.utoronto.ca/...rs-kyoto-prize-celebrated.html

awards & competition Kyoto University of Toronto

shared by Assunta Krehl on 14 Aug 09 - Cached
  • Toronto hosted a celebration Feb. 18 honouring Canada's first two Kyoto Prize laureates: University Professor Anthony Pawson of molecular genetics and McGill University's Charles Taylor, a philosopher.
  • Pawson, a world-renowned cell biologist and Mount Sinai Hospital distinguished investigator, received the prize in basic science for his studies of cellular communication. He will receive a 20-karat gold medal and a cash gift of 50 million yen (approximately $460,000 Cdn).
  • He and Taylor, who won the prize in the arts and philosophy category, delivered a joint lecture during the celebratory event at MaRs (Medical and Related Sciences Discovery District).
  • ...1 more annotation...
  • Pawson was recognized for his research into the way cells communicate with each other, which has made possible the development of drugs that halt the multiplication of certain types of cancer cells, among other breakthroughs. His lab has helped lay the groundwork for this new generation of drugs.
  • Assunta Krehl on 14 Aug 09
     
    University Professor Anthony Pawson of molecular genetics and McGill University's Charles Taylor, a philosopher where honoured as Canada's first two Kyoto Prize winners. Mention of Pawson and Taylor delivering a joint lecture at MaRS during the event.
  • Assunta Krehl on 14 Aug 09
     
    University Professor Anthony Pawson of molecular genetics and McGill University's Charles Taylor, a philosopher where honoured as Canada's first two Kyoto Prize winners. Mention of Pawson and Taylor delivering a joint lecture at MaRS during the event. Feb 20, 2009
Assunta Krehl

YFile - Symposium examines the path to breakthrough medicines - 0 views

www.yorku.ca/...index.asp

susan smith MaRS innovation collaboration science

shared by Assunta Krehl on 10 Aug 09 - Cached
  • Canada has the research expertise to develop drugs and vaccines to address pressing medical needs, but delivering on the promise will require new models of collaboration between scientists, biotechnology, the pharmaceutical industry, business and policy makers according to speakers at an upcoming symposium hosted by The Gairdner Foundation and York University. The symposium, Entrepreneurship & Commercialization in Biomedical Science, on Thursday, May 14, marks the 50th anniversary of both York University and The Gairdner Foundation.
  • The Gairdner Foundation recognizes the world's leading medical research scientists through its prestigious annual awards program for biomedical science. The symposium, which is hosted by York’s Faculty of Science & Engineering and Schulich School of Business, will bring together scientist entrepreneurs, Canadian venture capital firms, the biomedical industry and policy-makers.
  • He will be followed by Smith, founder and former president & CEO of RBC Ventures and a member of the board of Toronto's MaRS innovation centre. Smith will speak about how Canada has made strong progress in positioning itself as a potential leader in biotech and medical research and in its commercialization efforts but faces two clear threats – the global financial calamity together with the lack of clear federal government support for research.
  • Assunta Krehl on 10 Aug 09
     
    The symposium, Entrepreneurship & Commercialization in Biomedical Science, is being held on Thursday, May 14, which marks the 50th anniversary of both York University and The Gairdner Foundation. At this symposiums they will address the problem that Canadian researchers expertise to need to do in developing drugs and vaccines to address pressing medical needs. Mention of Susan Smith as a Board Member of MaRS Innovation.
Cathy Bogaart

Nonclinical IVDs: Growing interest in a growing field - 0 views

www.devicelink.com/...011.html

mars biotechnology

shared by Cathy Bogaart on 23 Apr 09 - Cached
  • Manufacturers of human IVD technologies have been contributing their skills and knowledge more and more to the nonclinical and agricultural diagnostic markets.
  • To learn more about why IVD manufacturers are making the switch from human diagnostics and testing to agricultural and other nonclinical diagnostics, IVD Technology editor Richard Park spoke with Rocky Ganske, president and CEO of Axela Inc. (Toronto)
    • Cathy Bogaart
      Cathy Bogaart on 23 Apr 09
       
      Axela is a MaRS client.
  • Our technology allows us to work directly in a variety of sample types that are difficult for other technologies to detect pathogens in without some additional sample preparation. So that led to people who were doing BSE (mad cow)–type testing asking if we could do tests for protein directly in matrices like milk or brain homogenate, and people asking for testing in plant extracts and things like that because other technologies don’t have that capacity.
  • ...2 more annotations...
  • Axela sells to the $20-billion life sciences market with its current platform, focusing first on protein-research applications, and enabling and capturing applications for downstream personalized medicine and human diagnostics.
  • Because it’s an attractive market, you see large diagnostic companies like Bayer Animal Health move some of its testing platforms that it would use for diagnostics into animal health testing
  • Cathy Bogaart on 23 Apr 09
     
    MaRS Client, Axela, talks about moving from human protein testing into the agricultural markets -- the challenges and the opportunities.
Assunta Krehl

Organs, heal thyselves - The Globe and Mail - March 8, 2010 - 0 views

m.theglobeandmail.com/...article1490636

life sciences Clients & Tenants Octane Medical Group regenerative medicine

shared by Assunta Krehl on 08 Mar 10 - No Cached
  • Assunta Krehl on 08 Mar 10
     
    Chris Atachison from the Globe and Mail reveals how Octane Medical Group, a biotechnology firm that makes regenerative medical products, analyzed an astronaut's health problem which led to their discover on how to help him med.
George Botos

Biotech, drug R&D grew in 2009 - Mass High Tech Business News - 1 views

www.masshightech.com/...tech-drug-RD-grew-in-2009.html

Life-Science biotech Investment

shared by George Botos on 18 Mar 10 - No Cached
  • Biotech, drug R&D grew in 2009
  • The R&D investments by PhRMA members and non-members in the pharmaceutical and biotech sectors reached a record $65.3 billion in 2009, an increase of 1.5 billion
  • there are more than 2,900 medicines in clinical trials or awaiting review
  • George Botos on 18 Mar 10
     
    The R&D investments by PhRMA members and non-members in the pharmaceutical and biotech sectors reached a record $65.3 billion in 2009, an increase of 1.5 billion despite the recession
‹ Previous 21 - 33 of 33
Showing 20▼ items per page